Boehringer Ingelheim announced the initiation of the AIRWARD Phase III clinical study, evaluating verducatib, an investigational oral dipeptidyl peptidase‑1 (DPP1) inhibitor, in adult patients with chronic obstructive pulmonary disease (COPD) who continue to experience exacerbations despite standard‑of‑care maintenance therapy and have blood eosinophil counts under 300 cells/µL.
Phase III Milestone
| Item | Detail |
|---|---|
| Sponsor | Boehringer Ingelheim (private, Germany) |
| Study | AIRWARD – Phase III clinical trial |
| Product | Verducatib (oral DPP1 inhibitor) |
| Indication | COPD in adults with exacerbations despite standard‑of‑care maintenance therapy; blood eosinophils < 300 cells/µL |
| Announcement Date | 3 Nov 2026 |
| Study Design Details | Not disclosed |
| Additional Program | AIRTIVITY Phase III trial in bronchiectasis |
Drug Profile & Mechanism of Action
- Molecule: Investigational oral DPP1 inhibitor that preferentially distributes to the bone marrow.
- First‑in‑Class Position: The first DPP1 inhibitor to enter Phase III clinical trials for COPD.
- Target Pathway: By inhibiting the DPP1 enzyme, verducatib blocks the activation of neutrophil serine proteases, aiming to reduce persistent neutrophil‑driven inflammation — a key pathway in COPD patients with blood eosinophil counts in the normal range (< 300 cells/µL).
- Intended Effect: Reduction of exacerbations and modulation of airway mucus production in COPD patients.
- Evidence Caveat: The mechanism of action is currently based on preclinical data; its clinical relevance has not yet been established.
Clinical Evidence & Unmet Need
| Attribute | Detail |
|---|---|
| Target Population | Adults with COPD experiencing exacerbations despite standard‑of‑care maintenance therapy |
| Biomarker Stratification | Blood eosinophil count < 300 cells/µL (non‑eosinophilic phenotype) |
| Primary Endpoint | Not disclosed |
| Sample Size / Sites | Not disclosed |
| Results | Not yet available – study recently initiated |
For the large segment of COPD patients whose inflammation is driven by neutrophils rather than eosinophils, inhaled corticosteroid‑centric regimens offer limited benefit, leaving exacerbation risk inadequately controlled. Verducatib’s bone‑marrow‑targeted approach seeks to intervene upstream, at the point where neutrophil serine proteases are activated, representing a mechanistically distinct strategy for this underserved phenotype.
Market Impact & Outlook
- Respiratory Franchise Expansion: The AIRWARD initiation extends Boehringer Ingelheim’s entrenched COPD portfolio into a novel oral anti‑inflammatory class, complementing its established inhaled maintenance therapies.
- Differentiated Mechanism: As the first DPP1 inhibitor in Phase III for COPD, verducatib faces no direct intra‑class competitor in this indication, positioning Boehringer ahead of potential followers.
- Pipeline Breadth: Parallel evaluation in the AIRTIVITY Phase III trial for bronchiectasis suggests a multi‑indication neutrophilic‑inflammation strategy across chronic respiratory diseases.
- Commercial Outlook: Revenue potential and timelines remain not disclosed, contingent on Phase III outcomes and future regulatory review.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical development plans, trial outcomes, and potential therapeutic benefits of verducatib. Actual results may differ materially due to risks including clinical trial performance, safety findings, regulatory requirements, and competitive dynamics. The mechanism of action described is based on preclinical data and has not been confirmed clinically. Verducatib is investigational and not approved by any regulatory authority.-Fineline Info & Tech
